Department of Medicine, University of Toronto, Ontario, Canada.
St Michael's Hospital, University of Toronto, Ontario, Canada.
Clin Infect Dis. 2019 Feb 15;68(5):748-756. doi: 10.1093/cid/ciy550.
Antimicrobial stewardship programs (ASPs) using audit and feedback in the intensive care unit (ICU) setting can reduce harms related to inappropriate antibiotic use. However, inappropriate discontinuation or narrowing of antibiotic treatment could increase infection-related mortality in this population. Individual ASP studies are underpowered to detect differences in mortality.
We conducted a systematic review and meta-analysis of audit and feedback in the ICU setting, using mortality as our outcome.
Of 2447 citations, 11 studies met our inclusion criteria. Although a variety of study designs were used to assess reductions in antibiotic use, mortality was analyzed using an uncontrolled before-after study design in all studies. Five studies directed audit and feedback to all or most ICU patients receiving antibiotics and measured overall ICU mortality. In the meta-analysis of these studies, the pooled relative risk of ICU mortality was 1.03 (95% confidence interval, .93-1.14). A second meta-analysis of 3 smaller studies that evaluated mortality only in patients directly assessed by the ASP found a pooled relative risk of ICU mortality of 1.06 (95% confidence interval, .80 to 1.4). Three studies were not appropriate for meta-analysis, but their results were consistent with our overall findings.
Our systematic review did not identify a change in mortality associated with antimicrobial stewardship using audit and feedback in the ICU setting. These results increase our confidence that audit and feedback can be safely implemented in this setting. Future studies should report standardized estimates of mortality and use more robust study designs to assess mortality, when feasible.
在重症监护病房(ICU)环境中使用审核和反馈的抗菌药物管理计划(ASPs)可以减少与不适当使用抗生素相关的危害。然而,不适当的停药或缩小抗生素治疗范围可能会增加该人群的感染相关死亡率。个体 ASP 研究在检测死亡率差异方面的能力不足。
我们对 ICU 环境中的审核和反馈进行了系统评价和荟萃分析,以死亡率为结局。
在 2447 条引文中有 11 项研究符合我们的纳入标准。尽管使用了各种研究设计来评估抗生素使用的减少,但所有研究都使用未对照的前后研究设计来分析死亡率。五项研究将审核和反馈针对所有或大多数接受抗生素治疗的 ICU 患者,并测量整体 ICU 死亡率。在这些研究的荟萃分析中,ICU 死亡率的合并相对风险为 1.03(95%置信区间,0.93-1.14)。对仅评估 ASP 直接评估的患者死亡率的 3 项较小研究的二次荟萃分析发现,ICU 死亡率的合并相对风险为 1.06(95%置信区间,0.80-1.4)。有 3 项研究不适合进行荟萃分析,但它们的结果与我们的总体发现一致。
我们的系统评价未发现 ICU 环境中使用审核和反馈与抗菌药物管理相关的死亡率变化。这些结果使我们更加相信,在这种情况下,可以安全地实施审核和反馈。未来的研究应报告标准化的死亡率估计值,并在可行的情况下使用更稳健的研究设计来评估死亡率。